A fourth shot’s protection against serious sickness did not fade after six weeks, but its defenses against infection did.
Israelis aged 60-plus could get a fourth Pfizer BioNTech vaccine from early 2022.
In new research, published today in NEJM, of nearly 1.2 million older Israelis, those given a fourth dose had 3.5 times lower rate of severe COVID-19 disease in the fourth week after treatment than those given a triple dose.
A fourth vaccine also held up against becoming infected – in the same timeframe, confirmed infection was twice as low compared to three doses.
The protection against serious illness from a fourth shot didn’t wane within six weeks, however, its defences against infection declined during this timespan.
Updating more soon…
Source: 10.1056/NEJMoa2201570
Image Credit: Getty
You were reading: Yearly Two vaccine shots are enough to prevent severe COVID – new study suggests
